Chronic CAD and PAD: Reducing Major Adverse Cardiovascular Events With Dual Pathway Inhibition Antithrombotic Therapy

Chronic CAD and PAD: Reducing Major Adverse Cardiovascular Events With Dual Pathway Inhibition Antithrombotic Therapy

Faculty

Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP
Professor of Pharmacy Practice and Science
College of Pharmacy
University of Nebraska Medical Center
Omaha, Nebraska
 
Program Description
Atherosclerosis often precipitates coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease, which are the 3 main types of cardiovascular disease. There are significant costs and substantial health burdens for patients and the health care system that are further compounded by interventions and hospitalizations. Although antiplatelet therapy has been the cornerstone of CAD and PAD management, overall morbidity and mortality remain problematic, and pharmacists need to be familiar with antithrombotic strategies using dual pathway inhibition. This activity will review guidelines for treatment of secondary prevention of CAD and PAD, as well as identification of when to recommend antithrombotic therapy, and counseling points pharmacists can provide to patients regarding lifestyle modifications for prevention of CAD and PAD.

Target audience: Health-system and retail pharmacists
Type of activity: Application
Release date: October 15, 2020
Expiration date: November 15, 2021
Time to complete activity: 2.0 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Examine the burden of coronary artery disease (CAD) and peripheral artery disease (PAD) along with suboptimal treatment in secondary prevention
• Compare the guidelines for secondary prevention in CAD and PAD and the most recent clinical data on dual pathway therapy
• Identify the pharmacist’s role for evaluating benefit versus risk in appropriate patients for CAD and PAD as well as the importance of medication therapy management

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-20-281-H01-P. The activity is available for CE credit through November 15, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty
Paul P. Dobesh, PharmD, FCCP, BCPS, BCCP, has the following relevant financial relationships with commercial interests to disclose: 

• Consultant – Boehringer Ingelheim, Janssen Pharmaceuticals, the Pfizer/BMS Alliance

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Liza Patel, PharmD, RPh; Kelly McCormick; Susan Pordon; Brianna Winters

Pharmacy Times® Editorial Staff—Davy James

Anonymous peer reviewers were part of the content validation and conflict resolution and have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms